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The title compound {systematic name: (+)-(S)-3-[5-cyano-2-
(4-¯uorophenyl)-1,3-dihydroisobenzofuran-2yl]propanaminium
oxalate oxalic acid 0.325-hydrate}, 2C20H22FN2O
+C2O42ÿ-
C2H2O40.325H2O, is a molecular salt of the N-protonated
escitalopram cation. As well as charge-balancing oxalate
dianions, neutral molecules of oxalic acid are present. The
component species interact by way of NÐH  O and short
OÐH  O hydrogen bonds, resulting in supramolecular
chains.
Comment
(+)-(S)-1-[3-(Dimethylammonio)propyl]-1-(4-¯uorophenyl)-5-
phthalan-5-carbonitrile oxalate (C20H21FN2O), common
names escitalopram or S-(+)-citalopram, is a widely prescribed
drug used to treat depression and related conditions (Burke,
2002). It is conveniently introduced as an oxalate salt, with a
nominal formula usually given as C20H21FN2OC2H2O4, i.e.
the presumed proton-transfer reaction is not speci®ed
(Sorbera et al., 2001). As part of our ongoing crystallographic
studies of pharmaceutical molecules (Harrison et al., 2005), we
now report the structure of the title compound, (I), in which
two N-protonated escitalopram cations (C20H22FN2O
+) and a
C2O4
2ÿ oxalate dianon are accompanied by a neutral molecule
of oxalic acid and a partially occupied water molecule (Fig. 1).
The bond lengths and angles in (I) fall within their expected
ranges (Cambridge Structural Database, Version 5.27; Allen,
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Figure 1
The molecular structure of (I), showing 50% probability displacement ellipsoids (arbitrary spheres for H atoms). All H atoms, except those involved in
hydrogen bonds (dashed lines), have been omitted for clarity.
2002). There are two C20H22FN2O
+ cations in the asymmetric
unit; atoms C8 and C28 are assumed to possess S con®gura-
tions, consistent with the known absolute structure of the
biologically active enantiomer of citalopram (Sanchez et al.,
2004). For the C1-containing molecule, the dihedral angle
between the mean planes of the C2±C7 and C9±C14 benzene
rings is 62.83 (13), and the C1/C2/C7/C8/O1 ®ve-membered
ring displays an envelope conformation with atom O1 in the
¯ap position [the displacement from the C-atom mean plane is
0.435 (5) AÊ ]. In the C21-containing molecule, the dihedral
angle between the C22±C27 and C29±C34 mean planes is
81.99 (13), and the envelope conformation for C21/C22/C27/
C28/O2 is less pronounced, with atom O2 displaced from the
C-atom mean plane by 0.113 (6) AÊ . The oxalate species are
both approximately planar; the dihedral angle between the
C41/O3/O4 and C42/O5/O6 groupings is 4.4 (3), and the
equivalent value for C43/O7/O8 and C44/O9/O10 is 2.8 (6).
The component species in (I) interact by way of NÐH  O
and OÐH  O hydrogen bonds (Table 1), such that both
C20H22FN2O
+ cations make bifurcated NÐH  (O,O)
hydrogen bonds to the same oxalate dianion. Then, the
2C20H22FN2O
+C2O42ÿ units are linked into [001] chains by
way of the oxalic acid molecules, i.e. the oxalate dianions and
oxalic acid molecules alternate in the chains (Fig. 2). The short
H  O separations of the oxalic acid-to-oxalate hydrogen
bonds suggests that they are strong interactions.
Although it is not expected from a consideration of the pKa
values of oxalic acid (pKa1 = 1.23 and pKa2 = 4.19; Newkome et
al., 1985) the co-existence of oxalate dianions and oxalic acid
molecules in the same crystal has been observed in a number
of compounds, three examples being bis(pyridinium) oxalate
oxalic acid (Newkome et al., 1985), barium oxalate oxalic acid
dihydrate (Chaix-Pluchery et al., 1989) and 1-(-pyrroli-
diniobenzyl)-2-naphthol oxalate oxalic acid (Periasamy et al.,
2004). These three compounds show the same alternating
oxalate±oxalic acid hydrogen-bonded chains seen in (I).
Experimental
The title compound was obtained as a gift sample from Jubilant
Organosys, Nanjangud, India. The sample of (I) was recrystallized
from ethanol (m.p. 420 K).
Crystal data
2C20H22FN2O
+C2O42ÿC2H2O4-
0.325H2O
Mr = 834.05
Monoclinic, P21
a = 7.9355 (3) AÊ
b = 24.7376 (9) AÊ
c = 11.1332 (5) AÊ
 = 106.589 (2)
V = 2094.54 (14) AÊ 3
Z = 2
Dx = 1.324 Mg m
ÿ3
Mo K radiation
 = 0.10 mmÿ1
T = 120 (2) K
Block, colourless
0.32  0.24  0.18 mm
Data collection
Nonius KappaCCD diffractometer
! and ’ scans
Absorption correction: multi-scan
(SADABS; Bruker, 2003)
Tmin = 0.969, Tmax = 0.982
7581 measured re¯ections
3609 independent re¯ections
2652 re¯ections with I > 2(I )
Rint = 0.037
max = 25.5

Re®nement
Re®nement on F 2
R[F 2 > 2(F 2)] = 0.042
wR(F 2) = 0.095
S = 1.02
3609 re¯ections
562 parameters
H atoms treated by a mixture of
independent and constrained
re®nement
w = 1/[2(F 2o) + (0.0473P)
2]
where P = (F 2o + 2F
2
c )/3
(/)max = 0.008
max = 0.17 e AÊ
ÿ3
min = ÿ0.21 e AÊ ÿ3
Extinction correction: SHELXL97
Extinction coef®cient: 0.0118 (16)
Anomalous dispersion effects were negligible and Friedel pairs
were merged before re®nement. The absolute structure of (I) was
assigned on the basis of the known chirality of escitalopram (Sanchez
et al., 2004). The C- and N-bound H atoms were placed in idealized
locations (CÐH = 0.95±0.99 AÊ and NÐH = 0.93 AÊ ) and re®ned as
riding with Uiso(H) values of 1.2Ueq(carrier) or 1.5Ueq(methyl C). The
oxalic acid H atoms were located in a difference map and re®ned with
the restraint OÐH = 0.90 (1) AÊ and the constraint Uiso(H) =
1.2Ueq(O). The H atoms of the partially occupied water molecule
could not be located.
Data collection: COLLECT (Nonius, 1998); cell re®nement:
SCALEPACK (Otwinowski & Minor, 1997); data reduction:
SCALEPACK and DENZO (Otwinowski & Minor, 1997), and
SORTAV (Blessing, 1995); program(s) used to solve structure:
SHELXS97 (Sheldrick, 1997); program(s) used to re®ne structure:
SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEP-3
(Farrugia, 1997); software used to prepare material for publication:
SHELXL97.
We thank the EPSRC National Crystallography Service
(University of Southampton) for data collection.
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Figure 2
A view along [010] of part of an [001] chain in (I), with hydrogen bonds
shown as dashed lines. Atoms labelled with an asterisk (*) are generated
by the symmetry operation (x, y, z ÿ 1).
Table 1
Hydrogen-bond geometry (AÊ , ).
DÐH  A DÐH H  A D  A DÐH  A
N1ÐH1  O6 0.93 1.91 2.768 (4) 152
N1ÐH1  O4 0.93 2.22 2.886 (4) 128
N3ÐH2  O3 0.93 1.91 2.764 (4) 152
N3ÐH2  O5 0.93 2.22 2.884 (4) 127
O7ÐH3  O5 0.91 (3) 1.56 (3) 2.466 (4) 177 (4)
O9ÐH4  O4i 0.91 (3) 1.57 (3) 2.465 (4) 173 (4)
Symmetry code: (i) x; y; z 1.
Supplementary data for this paper are available from the IUCr electronic
archives (Reference: GD3075). Services for accessing these data are
described at the back of the journal.
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